Biovica International
15.9.2021 08:21:46 CEST | ACCESS Newswire | Press release
UPPSALA, SE / ACCESSWIRE / September 15, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announces that DiviTum®TKa results from an analysis of samples from the large SWOG S0226 study have been published in the highly ranked peer-reviewed scientific journal Clinical Cancer Research, published by the American Association for Cancer Research (AACR). The strong results support using DiviTum®TKa as a tool to monitor disease progression with endocrine therapy in women with hormone receptor positive metastatic breast cancer.
"SWOG researchers have demonstrated that a blood serum test can identify which of these patients have slow-growing disease that might be controlled with a simple aromatase inhibitor pill alone," said co-author of the paper, Dr. Lajos Pusztai, MD, PhD, Yale University Cancer Center.
"We are very proud to see the strong DiviTum®TKa results being published in Clinical Cancer Research. This highly reputable scientific journal by AACR focuses on innovative clinical and translational research bridging the laboratory and the clinic. The publication is a great recognition for DiviTumTKa and an important step to establishing the test as a standard tool for monitoring treatment of metastatic breast cancer to the benefit of patients and payers," said Anders Rylander, CEO of Biovica.
As previously announced, results demonstrate that patients with low TKa levels (using a predefined cut-off) before treatment initiation will do significantly better than patients expressing high levels of TKa. Progression free survival (PFS) was 17.3 vs 11.2 months and overall survival (OS) was 58 vs 30 months, respectively. In addition, similar results were observed during treatment, where patients with low TKa showed significantly longer PFS and OS. Furthermore, results support the potential clinical use of DiviTum®TKa to identify low-TKa patients as best suited for endocrine monotherapy, whereas those with elevated TKa values appear to benefit from combination therapies.
The analysis measured thymidine kinase activity (TKa) levels in 1,726 serum samples from more than 400 patients in SWOG S0226 and is the largest study to evaluate DiviTum®TKa for prognostic and serial monitoring of metastatic breast cancer. The study constitutes the foundation for the clinical validation of DiviTum®TKa in Biovica's 510(k)-application to the FDA. DiviTum®TKa is 510(k) pending. Not available for sale in the United States.
Link to study: Clinical Cancer Research
Contact
Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .
SOURCE: Biovica International
View source version on accesswire.com:
https://www.accesswire.com/664165/DiviTumRTKa-Results-from-SWOG-Study-Published-in-Clinical-Cancer-Research
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications7.5.2026 22:05:00 CEST | Press release
Integrated lidar and modular drone platforms enable scalable autonomy, mapping, and navigation across complex real-world environments REDMOND, WA AND EINDHOVEN, THE NETHERLANDS / ACCESS Newswire / May 7, 2026 / MicroVision, Inc., (Nasdaq:MVIS), a leader in advanced perception solutions, today announced the signing of a Memorandum of Understanding (MoU) with Avular Innovations B.V. to integrate their technologies and accelerate the development of next-generation autonomous systems for civil infrastructure and global commercial applications. By combining MicroVision's high-performance, solid-state lidar, optimized for reduced energy usage and increased operational efficiency, with Avular's modular drone platforms and system integration expertise, the companies are creating a flexible, scalable solution designed to address real-world operational challenges across global markets. The collaboration focuses on delivering advanced capabilities, including autonomous mission execution in GPS-de
Innodata Reports Record First Quarter 2026 Results7.5.2026 22:05:00 CEST | Press release
Revenue Up 54% Year-Over-Year, Beats Consensus by 18% Adjusted EBITDA of $25.0 Million Beats Consensus by 139%; Adjusted Gross Margin Expands to 47% Raises Full-Year 2026 Revenue Growth Guidance to ~40% or More, Up From ~35% or More Announces New Engagements With Big Tech Company Expected to Generate Approximately $51 Million of Revenue in 2026 NEW YORK, NY / ACCESS Newswire / May 7, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2026. Revenue of $90.1 million, representing 54% year-over-year revenue growth. Adjusted Gross Profit of $42.6 million, representing Adjusted Gross Margin of 47%.* Adjusted EBITDA of $25.0 million, or 28% of revenue, an increase of $12.3 million from $12.7 million in the same period last year.* Net income of $14.9 million, or $0.46 per basic share and $0.42 per diluted share, compared to net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, in the same period last year. Cash, cash equ
Ostathi, Operated by UniHouse, Pioneers the Middle East's First Digital Infrastructure Linking Structured Workforce Development to Verified Income7.5.2026 18:30:00 CEST | Press release
World Bank and Jordan Ministry of Digital Economy-Funded Programme - Delivering the Region's First Auditable Connection Between Structured Capacity Development and Verified Income LONDON, UK / ACCESS Newswire / May 7, 2026 / Ostathi, owned and operated by UniHouse, today announced the live national deployment of a proprietary digital ledger infrastructure in Jordan - a first-of-its-kind system across the Middle East and Africa that connects an individual's structured capacity development, competency certification, gig economy and marketplace participation, and income generation into a single, auditable digital chain, integrated directly with regulated national fintech platforms. Ostathi Jordan - live deployment under the World Bank Youth, Technology and Jobs programme in partnership with Jordan's Ministry of Digital Economy and Entrepreneurship. The deployment is funded under the World Bank Youth, Technology and Jobs (YTJ) Project in partnership with Jordan's Ministry of Digital Econom
Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook7.5.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2026. First Quarter 2026 Net sales of $156.1 million, up 36.1% compared to the prior year's quarter. Net income of $11.1 million, compared to $15.3 million for the prior year's quarter, primarily resulting from higher interest, higher non-cash amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Diluted earnings per share of $0.12 compared to $0.16 for the prior year's quarter, primarily resulting from higher interest, higher amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Adjusted EBITDA of $63.2 million, up 46.6% compared to the prior year's quarter. Net income margin of 7.1% compared t
Able Device Introduces SIMbae(TM), Enabling Deterministic AI Execution at the Identity Layer7.5.2026 14:15:00 CEST | Press release
From Connectivity Management to Execution. AI predicts. SIMbae enforces. RALEIGH, NC / ACCESS Newswire / May 7, 2026 / Able Device today announced a major evolution of its SIMbae™ technology, introducing AI-driven connectivity execution directly within the SIM/eSIM secure element - transforming the SIM into a deterministic enforcement engine for intelligent mobile networks. Across the telecom industry, artificial intelligence is rapidly being adopted to analyze network data, predict device behavior, and recommend connectivity optimizations. However, a critical gap remains: while AI generates insights, there has been no universal mechanism to enforce those decisions consistently across devices, networks, and geographies. SIMbae closes that gap. By embedding deterministic policy execution inside the SIM - the most widely deployed secure element - SIMbae turns AI insight into real-world device behavior without requiring applications or device firmware changes. AI predicts. SIMbae enforces
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom